Overview

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2030-07-01
Target enrollment:
Participant gender:
Summary
This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).
Phase:
PHASE2
Details
Lead Sponsor:
Alliance Foundation Trials, LLC.
Collaborator:
AstraZeneca
Treatments:
durvalumab